# Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

> **NCT03509012** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 105 (actual)

## Conditions studied

- Carcinoma, Squamous Cell of Head and Neck
- Carcinoma, Non-Small-Cell Lung
- Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab
- **DRUG:** Cisplatin (dose level 4)
- **DRUG:** Cisplatin (dose level 3)
- **DRUG:** Carboplatin (dose level 1)
- **DRUG:** Carboplatin (dose level 2)
- **DRUG:** Etoposide (dose level 1)
- **DRUG:** Etoposide (dose level 2)
- **DRUG:** Paclitaxel
- **DRUG:** Pemetrexed
- **RADIATION:** External beam radiation (dose level 1)
- **RADIATION:** External beam radiation (dose level 2)
- **RADIATION:** External beam radiation (hyperfractionated)
- **DRUG:** Cisplatin (dose level 1)
- **DRUG:** Cisplatin (dose level 2)
- **RADIATION:** External beam radiation (standard)

## Key facts

- **NCT ID:** NCT03509012
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-02
- **Primary completion:** 2020-12-31
- **Final completion:** 2025-01-08
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2025-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03509012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03509012, "Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03509012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*